These plans come as part of AstraZeneca’s planned $50bn US manufacturing investment, which the company announced in July.
The US Food and Drug Administration (FDA) has approved PADCEV (enfortumab), in combination with Keytruda (pembrolizumab) or Keytruda QLEX (pembrolizumab and berahyaluronidase), as a treatment for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback